Alphatec Holdings (ATEC) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.09
- Estimate
- $0.09
- Surprise
- -2.0%
- Revenue (period 2026-09-30)
- $221.2M
- Score at report (before → after)
- 6.3 → 6.2/10
Revenue source: xbrl.
How the report landed
Alphatec Holdings (ATEC) reported adjusted EPS of $0.09, in line with the $0.09 estimate. TrendMatrix's engine moved from Hold (6.3/10) to Sell at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ATEC Sell at 6.2/10.
1 of the last 4 quarters beat the estimate; this quarter's -2.0% surprise compares with a +36.1% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Supplier: Invibio
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0)
- Leverage penalty (D/E 52.4): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.37
- Price target
- $13.73
- Stop
- $10.57
- Upside to target
- +20.8%
- Reward-to-risk
- 1.5:1
Risk check: trading volume is running 2.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
ATEC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.75B
- P/E (fwd)
- 19.0
- 52-week range
- $6.82–$23.29
- Off 52-week high
- 51.2%
- RSI (14)
- 58
- Volume vs avg
- 2.60×
- Score today
- 6.2/10